Doctors told Don Wright he had five years to live when he was diagnosed with multiple myeloma in 2003. Instead of resigning himself to this…
News
The U.S. Food and Drug Administration (FDA) has accepted a supplemental biologics license application (sBLA) seeking to expand the currently approved indication of Xgeva…
The U.S. Federal Drug Administration has approved a combination of the immunotherapies Darzalex (daratumumab), Pomalyst (pomalidomide) and dexamethasone as a multiple myeloma treatment, according to…
Dragonfly Therapeutics and Celgene have teamed up to develop therapies for multiple myeloma and other blood cancers. The partners will use Dragonfly’s TriNKET immunotherapy…
Massachusetts–based Karyopharm Therapeutics announced that the first patient was dosed in its pivotal BOSTON Phase 3 clinical trial…
John Theurer Cancer Center and MedStar Georgetown University Hospital have announced the completion of the 100th blood stem cell transplant since its joint…
Merck has suspended patient enrollment in two Phase 3 clinical trials, KEYNOTE-183 and KEYNOTE-185, testing Keytruda (pembrolizumab) in combination with other therapies in patients…
Caris Life Sciences is collaborating with the National Cancer Institute (NCI) to identify patients eligible to participate in the Phase 2 NCI-MATCH (Molecular Analysis for Therapy Choice) study,…
Updated results from an ongoing Phase 1 clinical study of bb2121, an investigational therapy for the treatment of multiple…
An ongoing Phase 1 trial testing a novel CAR T-cell therapy has shown promising results in relapsed or treatment-resistant (refractory) multiple myeloma patients. The new anti-BCMA…
